TRXC - TransEnterix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3300
+0.0011 (+0.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3289
Open0.3355
Bid0.3215 x 3100
Ask0.3500 x 800
Day's Range0.3150 - 0.3400
52 Week Range0.2800 - 33.2800
Volume412,820
Avg. Volume2,174,563
Market Cap15.21M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-8.6940
Earnings DateMar 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
  • Thomson Reuters StreetEvents

    Edited Transcript of TRXC earnings conference call or presentation 16-Mar-20 8:30pm GMT

    Q4 2019 Transenterix Inc Earnings Call

  • Business Wire

    TransEnterix, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2019

    TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the fourth quarter and full-year 2019.

  • ACCESSWIRE

    TransEnterix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 16, 2020 / TransEnterix, Inc. (AMEX:TRXC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at 4:30 PM ...

  • Company News for Mar 16, 2020
    Zacks

    Company News for Mar 16, 2020

    Companies in the news are: BKE, ORCL, TLYS, TRXC

  • Benzinga

    TransEnterix, Inc. Common Stock Earnings Preview

    TransEnterix, Inc. (AMEX: TRXC) unveils its next round of earnings this Monday, March 16. Get prepared with Benzinga's ultimate preview for TransEnterix, Inc. Common Stock's Q4 earnings.Earnings and Revenue TransEnterix, Inc. Common Stock earnings will likely be near a loss of 0.620 cents per share while revenue will be around $3.90 million, according to analysts.View more earnings on TRXCIn the same quarter last year, TransEnterix, Inc. Common Stock posted EPS of 7 cents on sales of $7.52 million. Revenue would be down 48.17% on a year-over-year basis. TransEnterix, Inc. Common Stock's reported EPS has stacked up against analyst estimates in the past like this: Quarter Q3 2019 Q2 2019 Q1 2019 Q4 2018 EPS Estimate -0.080 -0.080 -0.080 -0.06 EPS Actual -0.090 -0.100 -0.090 -0.07 Stock Performance Shares of TransEnterix, Inc. Common Stock were trading at 0.355 cents per share as of March 16. Over the last 52-week period, shares are down 83.94%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with TransEnterix, Inc. Common Stock. The strength of this rating has maintained conviction over the past three months.Conference Call TransEnterix, Inc. Common Stock is scheduled to hold a conference call at 4:30 p.m. ET and can be accessed here: https://edge.media-server.com/mmc/p/spz6z5w9See more from Benzinga * Stocks That Hit 52-Week Lows On Friday * Stocks That Hit 52-Week Highs On Friday * Benzinga's Top Upgrades, Downgrades For March 13, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Business Wire

    TransEnterix Receives FDA Clearance for First Machine Vision System in Robotic Surgery

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company received 510(k) clearance for the Intelligent Surgical Unit (ISUTM) that enables machine vision capabilities on the SenhanceⓇ Surgical System.

  • Business Wire

    TransEnterix Schedules Fourth Quarter and Fiscal Year 2019 Financial and Operating Results Conference Call for March 16, 2020

    TransEnterix, Inc. (NYSE American: TRXC) announced today that it plans to release fourth quarter financial and Fiscal year 2019 operating results after the market closes on Monday, March 16, 2020. The Company will host a conference call to discuss these results starting at 4:30 p.m. Eastern Time the same day. The call will be concurrently webcast.

  • Business Wire

    TransEnterix Announces Pricing of $15 Million Underwritten Public Offering

    TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has priced its previously announced underwritten offering of units. The offering was comprised of (i) units of common stock and warrants to purchase shares of common stock and (ii) units of convertible preferred stock and warrants to purchase shares of common stock.

  • Business Wire

    TransEnterix Announces Launch of Underwritten Public Offering

    TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has commenced an underwritten offering of units. The offering is expected to be comprised of (i) a unit of common stock and warrants to purchase shares of common stock and (ii) a unit of convertible preferred stock and warrants to purchase shares of common stock. The unit of convertible preferred stock and warrants is being offered in lieu of the unit of common stock and warrants for those purchasers who would otherwise beneficially own more than 4.99% (or, at the election of the purchaser 9.99%). The preferred stock to be issued in the offering, if any, includes a beneficial ownership blocker but has no dividend rights (except to extent dividends are also paid on the common stock),voting rights, liquidation preference or other preferences over common stock.

  • Business Wire

    TransEnterix Announces St. Marianna University School of Medicine Toyoko Hospital in Japan to Initiate a Senhance Digital Laparoscopy Program

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the St. Marianna University School of Medicine Toyoko Hospital, a hospital in the greater Tokyo metropolitan area, has entered into an agreement to lease and utilize a Senhance® Surgical System.

  • Business Wire

    TransEnterix Announces Kitakyushu General Hospital Completes First Surgical Procedures with the Senhance Surgical System

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Kitakyushu General Hospital, a hospital in southwestern Japan, completed its first surgical procedures using the Senhance® Surgical System. The first patients were treated by Dr. Naoki Nagata, President of Kitakyushu General Hospital, and team across general and colorectal minimally invasive surgical procedures. TransEnterix had announced on January 29, 2020 that Kitakyushu General Hospital had entered into an agreement to lease and utilize a Senhance System.

  • Business Wire

    TransEnterix Announces CE Mark Approval for Pediatric Indication for Senhance Surgical System

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Company received CE Mark approval for an expanded indication to treat pediatric patients above 10kg (approximately 22 lbs) with the Senhance® System.

  • Business Wire

    TransEnterix Announces Common Stock Purchase Agreement by Lincoln Park Capital Fund, LLC

    TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced today that it has entered into a common stock purchase agreement ("Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), a Chicago-based institutional investor.

  • When Does Market Timing Actually Work? - February 05, 2020
    Zacks

    When Does Market Timing Actually Work? - February 05, 2020

    Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

  • How to Time the Markets Like an Investing Pro - January 17, 2020
    Zacks

    How to Time the Markets Like an Investing Pro - January 17, 2020

    In the long-run, does consistent market timing really matter to be a successful investor?

  • Benzinga

    The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...

  • The Market Timing Secrets No One Talks About - December 24, 2019
    Zacks

    The Market Timing Secrets No One Talks About - December 24, 2019

    Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

  • Transenterix Inc (TRXC): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Transenterix Inc (TRXC): Are Hedge Funds Right About This Stock?

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]